CLINICAL TRIAL HIGHLIGHTS: O.2 IGNITE DMD Phase I/II ascending dose study of SGT-001 microdystrophin gene therapy for DMD: 1.5-year functional outcomes update
| Autor: | Rao, V., Byrne, B., Shieh, P., Salabarria, S., Berthy, J., Corti, M., Redican, S., Lawrence, J., Brown, K., Shanks, C., Spector, S., Gonzalez, P., Schneider, J., Morris, C., Clary, C. |
|---|---|
| Zdroj: | In Neuromuscular Disorders October 2021 31 Supplement 1:S47-S47 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect